During the double-blind period of ATAMS , annualised relapse rates were higher in the atacicept groups than in the placebo group ( atacicept 25 mg , 086 , 95 % CI 043-174 ; 75 mg , 079 , 040-158 ; 150 mg , 098 , 052-181 ; placebo , 038 , 017-087 ) .